Trial Profile
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Pinometostat (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 02 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 02 Jun 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.